CD99 Mouse Monoclonal Antibody [Clone ID: 3B2/TA8]
CAT#: AM26145PU-N
CD99 mouse monoclonal antibody, clone 3B2/TA8, Purified
Conjugation: APC
Need it in bulk or conjugated?
Get a free quote
CNY 3,140.00
货期*
5周
规格
Specifications
Product Data | |
Clone Name | 3B2/TA8 |
Applications | FC |
Recommend Dilution | Flow cytometry. |
Reactivity | Human |
Host | Mouse |
Clonality | Monoclonal |
Immunogen | Human thymocytes |
Specificity | This antibody recognizes CD99, an approximately 32 kDa sialoglycoprotein expressed on many cell types, with particularly strong expression on Ewing´s sarcoma and peripheral primitive neuroectodermal tumors. Within the hematopoietic system, CD99 is expressed on virtually all cell types except granulocytes. |
Formulation | Phosphate buffered saline (PBS) with 15 mM sodium azide, approx. pH 7.4 State: Purified State: Liquid Ig fraction |
Concentration | lot specific |
Purification | Protein-A affinity chromatography |
Conjugation | Unconjugated |
Storage Condition | Store undiluted at 2-8°C. DO NOT FREEZE! |
Gene Name | CD99 molecule |
Database Link | |
Background | CD99 is a ubiquitous transmembrane type I sialoglycoprotein of a unique and poorly characterized protein family. CD99 is heavily O-glycosylated and was described as a T cell costimulator and strong activator of integrin-mediated actin cytoskeleton assembly, promoting cell adhesion and homotypic aggregation, immediate arrest on an inflamed vascular endothelium, and cell migration through it. Ligation of CD99 under some conditions can lead to apoptosis. Originally CD99 was described as a human thymus leukemia antigen, an Ewing´s sarcoma-specific membrane marker, and an adhesion molecule involved in spontaneous rosette formation of T cells with erythrocytes. |
Synonyms | E2 antigen, 12E7, MIC2X, MIC2Y |
Reference Data | |
Protein Families | Druggable Genome, Transmembrane |
Protein Pathways | Cell adhesion molecules (CAMs), Leukocyte transendothelial migration |
Documents
Product Manuals |
FAQs |
SDS |
Resources
抗体相关资料 |
Customer
Reviews
Loading...